Slide 1: First Quarter 2023 Results Conference Call and Webcast
First Quarter 2023 Results Conference Call and Webcast May 8, 2023 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Chris Astle, Ph.D., Senior Vice President & Chief Financial Officer
Chris Astle, Ph.D. Senior Vice President & Chief Financial Officer Making a Meaningful Difference 3
Slide 4: First Quarter 2023 Financial Results
First Quarter 2023 Financial Results In millions USD 1Q22 1Q23 • Revenue in 1Q23 primarily driven by $34.4 million in revenue from zanidatamab development support and Revenue $1.9 $35.6 drug supply payments from Jazz • R&D Expense decrease primarily related to lower manufacturing and CRO expenses, a
Slide 5: Focused ADC and MSAT Portfolio Driving "5 by 5" Development Strategy
Focused ADC and MSAT Portfolio Driving “5 by 5” Development Strategy Robust Pipeline Azymetric™ → Multispecifics Antibody-Drug Conjugates ZW251 ZW191 Zanidatamab ZymeLink™ Zovodotin ZW220 TOPO1i Auristatin Platform Hemiasterlin Site Specific TLR7 Conjugation ISAC 2 + 1 T Cell Engager (ZW171) Drug Co
Slide 6: Zanidatamab: Recent Data Continue to Support Broad Activity in HER2-expressing Cancers
Zanidatamab: Recent Data Continue to Support Broad Activity in HER2-expressing Cancers HERIZON-BTC-01 Preliminary Phase 1b/2 data in 1L mBC December 2022 Top-line Data Updated data to be presented by BeiGene at ASCO 2023 • cORR of 41.3% [95% CI: 30.4, 52.8] • cORR of 90.5% [95% CI: 69.6, 98.8] • mDO
Slide 7: Important Anticipated Milestones & Opportunities Throughout Product Pipeline
Important Anticipated Milestones & Opportunities Throughout Product Pipeline 2023 2024 • Phase 2 1L GEA Follow-Up • Submit 2 IND Applications (presented January 19 at ASCO GI) for ZW171 and ZW191 zanidatamab + chemotherapy • HERIZON-GEA-01 • Additional publications on preclinical development Anticip
Slide 8: Q&A
Q&A Kenneth Galbraith Chair and CEO Neil Klompas President and COO Chris Astle, Ph.D. SVP and CFO Paul Moore, Ph.D. CSO Making a Meaningful Difference 8